The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial.
 
Lisanne P. Zijlker
No Relationships to Disclose
 
Winan J. van Houdt
Consulting or Advisory Role - Amgen (Inst); belpharma (Inst); Sanofi/Aventis (Inst)
Speakers' Bureau - Boehringer Ingelheim (Inst); MSD (Inst); Novartis (Inst)
 
Emma H.A. Stahlie
No Relationships to Disclose
 
Viola Franke
No Relationships to Disclose
 
Maartje W. Rohaan
No Relationships to Disclose
 
Antonios Delatzakis
No Relationships to Disclose
 
Charlotte Zuur
Research Funding - Bristol-Myers Squibb (Inst)
 
Willem M.C. Klop
No Relationships to Disclose
 
Bart A. van de Wiel
Employment - BMSi
 
Anke Kuijpers
No Relationships to Disclose
 
Elianne de Boer
No Relationships to Disclose
 
Johannes V. van Thienen
No Relationships to Disclose
 
John B. A. G. Haanen
Stock and Other Ownership Interests - Neogene Therapeutics
Consulting or Advisory Role - Achilles Therapeutics (Inst); bioNTech (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Ipsen (Inst); Molecular Partners (Inst); MSD Oncology (Inst); Neogene Therapeutics; Novartis (Inst); Pfizer (Inst); POEM Health (Inst); Roche/Genentech (Inst); Sanofi (Inst); T-Knife (Inst); Third Rock Ventures (Inst)
Research Funding - Amgen (Inst); Asher Biotherapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Alexander Christopher Jonathan Van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst); MSD Oncology (Inst); Novartis (Inst); Pierre Fabre (Inst); Provectus Biopharmaceuticals; Sanofi (Inst); Sirius Medical (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis